One of the key players in an investigation of counterfeit Avastin that appeared to have been imported into the U.S. by a Canadian Internet pharmacy has pleaded guilty to playing a part in the operation.
Regulators have again turned down Roche's cancer drug Avastin for payment by the National Health System (NHS), this time for use on a recurrent, advanced ovarian cancer. But that doesn't mean patients won't get it.
The effects of a nasty flu season may wear off quickly, but two newly launched breast cancer drugs should help to keep the oncology increases coming.
Alarm over counterfeits coming into the U.S. through Canadian Internet pharmacies reached new levels last year after a counterfeit version of the cancer drug Avastin made its way here through one. But even as efforts are made to buttress protections against that weak link in the pharmaceutical supply chain, state officials in Maine are working to change the state's legislation so its public employee health programs can keep buying drugs from a Canadian Internet pharmacy.
The FDA has come down hard on a compounding pharmacy that repackaged Roche's cancer drug Avastin for ophthalmic use. With serious eye infections reported in 5 patients injected with the drug, Clinical Specialties is recalling dozens of lots of the Avastin syringes.
Big Pharma sees drug counterfeiting as a big problem as international criminals find new ways to get fake drugs, even counterfeit cancer meds, into the legitimate supply chain. Now more than two dozen drugmakers are chipping in dollars, euros and pounds to help the international crime fighter Interpol do a better job of tracking them down.
Italian antitrust watchdogs have entered the Avastin-vs.-Lucentis fray. The Italian Competition Authority opened an investigation of Roche ($RHHBY) and Novartis ($NVS) on suspicion of a "cartel" designed to preference the vision-loss drug Lucentis over Avastin, the cancer drug sometimes used off-label in eye treatments.
A new small-molecule drug developed by cancer researchers has a remarkable effect in mice--it jump-starts a tumor-destroying system in the body, essentially driving cancer cells to suicide while protecting healthy tissue.
Two individuals have pleaded guilty in separate cases to importing and selling $7 million worth of unapproved oncology drugs to doctors in the U.S., shedding light on the perils of doctors buying foreign-made drugs and thinking they are getting equal quality at lower prices.
Could Avastin be on its way to another indication? On the heels of a broader approval for the drug in ovarian cancer in the EU, the U.S. National Institutes of Health has unveiled data showing Avastin helped patients with advanced cervical cancer live longer.